书签 分享 收藏 举报 版权申诉 / 69
上传文档赚钱

类型大学精品课件:生物工程制药课件:lec 1 2013 old.ppt

  • 上传人(卖家):罗嗣辉
  • 文档编号:5259813
  • 上传时间:2023-03-01
  • 格式:PPT
  • 页数:69
  • 大小:587KB
  • 【下载声明】
    1. 本站全部试题类文档,若标题没写含答案,则无答案;标题注明含答案的文档,主观题也可能无答案。请谨慎下单,一旦售出,不予退换。
    2. 本站全部PPT文档均不含视频和音频,PPT中出现的音频或视频标识(或文字)仅表示流程,实际无音频或视频文件。请谨慎下单,一旦售出,不予退换。
    3. 本页资料《大学精品课件:生物工程制药课件:lec 1 2013 old.ppt》由用户(罗嗣辉)主动上传,其收益全归该用户。163文库仅提供信息存储空间,仅对该用户上传内容的表现方式做保护处理,对上传内容本身不做任何修改或编辑。 若此文所含内容侵犯了您的版权或隐私,请立即通知163文库(点击联系客服),我们立即给予删除!
    4. 请根据预览情况,自愿下载本文。本站不保证下载资源的准确性、安全性和完整性, 同时也不承担用户因使用这些下载资源对自己和他人造成任何形式的伤害或损失。
    5. 本站所有资源如无特殊说明,都需要本地电脑安装OFFICE2007及以上版本和PDF阅读器,压缩文件请下载最新的WinRAR软件解压。
    配套讲稿:

    如PPT文件的首页显示word图标,表示该PPT已包含配套word讲稿。双击word图标可打开word文档。

    特殊限制:

    部分文档作品中含有的国旗、国徽等图片,仅作为作品整体效果示例展示,禁止商用。设计者仅对作品中独创性部分享有著作权。

    关 键  词:
    大学精品课件:生物工程制药课件:lec 2013 old 大学 精品 课件 生物工程 制药 lec
    资源描述:

    1、An Introductory Course ofPharmaceutical BiotechnologyGrading policynIn-class performance and assignments account for 30 points.nFinal examination takes up 70 points.Your teacher:nLiu Qiuyun刘秋云Associate ProfessorThe Key Laboratory of Gene Engineering of Ministry of EducationTel:84110296nEmail: n地址:曾宪

    2、梓堂北院308nTeaching Website:BlackboardWhat is Biotechnology?nBiotechnology is a fascinating field which is at the cutting edge of science,using living cells and materials produced by cells to create pharmaceutical,diagnostic,agricultural,environmental,and other products to benefit society.What is Biote

    3、chnology?nPeople working in this field make groundbreaking discoveries that fight disease,improve food production,clean up the environment and make manufacturing more efficient and profitable.What is Biotechnology?nThe science of biotechnology is also used to alter genetic information in animals and

    4、 plants to improve them in some way that benefits people.Because biotechnology essentially uses the basic ingredients of life to make new products,it is both a cutting-edge technology and an applied science.What are the latest trends What are the latest trends in the field?in the field?nThe field of

    5、 biotechnology for health care is a particularly active field.Drugs play a huge role in the entire health care market as new therapies are often aimed at reducing hospital and other medical intervention as people age.Numerous protein and peptide therapeutics have been released to the market in the p

    6、ast 30 years,and hundreds of biopharmaceuticals enter clinical trials each year.Functional genomics and proteome will fuel the growth in this field.What can you expect fornThe innovative,high-growth,research and development biotechnology industry is especially reliant on skilled individuals to fill

    7、a variety of roles including basic operations,research,and commercialization.If there is one constant in the biotechnology industry,it is change.What will help me prepare for the course?nCourses like gene engineering,genetics,microbiology and so on will help.In addition,any previous experience in a

    8、related work environment or lab will be beneficial.参考书n1.自编英文讲义。n2.生物技术制药/郭葆玉主编,北京:清华大学出版社,2011年。n3.生物技术制药概论/姚文兵主编,北京:中国医药科技出版社,2010年。n4.生物制药工程技术/刘彦昌、林佳、龚乃超主编,武汉:华中师范大学出版社,2009。Recommended booksn5.Nature Biotechnology.6.Crommelin,Daan J.A.(EDT)/Sindelar,Robert D.(EDT)/Meibohm,Bernd(EDT)2007,Pharmace

    9、utical biotechnology ISBN:142004437.7.Carlos Alberto Guzmn,Giora Z.Feuerstein,Pharmaceutical biotechnology,Springer,2009,ISBN 1441911316,9781441911315.8.Gary Walsh,Pharmaceutical biotechnology:concepts and applications,John Wiley and Sons,2007,ISBN 0470012447,9780470012444.9.Austin,Martin,Business D

    10、evelopment for the Biotechnology and Pharmaceutical Industry,ISBN:9780566087813 Online classesnhttp:/ journals nNaturenSciencenNature BiotechnologynNature MedicinenTrends in BiotechnologynCurrent opinion in BiotechnologyRecommended websitesnhttp:/ Development ofBiotechnologyn1.Biotechnological produ

    11、ction of foods and beveragesn Beer making by 6000 B.C.n Bread baking by 4000 B.C.n Wine makingn Soy saucen Cheese productionn Mushroom productionHistorical development ofBiotechnologyn2.Biotechnological processes initially developed under non-sterile conditionsn ethanol,acetic acid,butanol and aceto

    12、newere produced by open microbialfermentation processesn waste-water treatment and composting(土壤堆肥法)of solid wastes by use of microorganismsHistorical Development ofBiotechnologyn3.Introduction of sterility to biotechnological processesnIn the 1940s complicated engineering techniques were introduced

    13、 to the mass cultivation of microorganisms to exclude contaminating microorganisms.Historical Development ofBiotechnologyn4.Applied genetics and recombinant DNA technology Traditional strain improvement of important industrial organisms New programming of the biological properties of organismsBiotec

    14、hnologyn an interdisciplinary,applications-orientedscience that involves avariety of fields,such asmicrobiology,biochemistry,molecular biology,genetic engineering,technical chemistry and process technology.FDA-ApprovedBiopharmaceuticalsn More than 325 million people worldwide have been helped by the

    15、 several hundreds of biotechnology drugs and vaccines approved by the U.S.Food and Drug Administration(FDA).n Of the biotech medicines on the market,70 percent were approved in the last six years.Biopharmaceuticalsin clinical trialsnThere are more than 400 biotech drug products and vaccines currentl

    16、y in clinical trials targeting more than 200 diseases,includingn various cancers Alzheimers diseasen heart disease diabetesn multiple sclerosis AIDSn arthritisBiotechnology diagnostic productsnBiotechnology is responsible for hundreds of medical diagnostic tests.Keep the blood supply safe from the A

    17、IDS virus and detect other conditions early enough to be successfully treated.Home pregnancy tests are also biotechnology diagnostic products.Biotechnology Companies(2006)nThere are 1,452 biotechnology companies in the United States,of which 336 are publicly held.U.S.Biotechnology CompaniesMarket ca

    18、pitalizationnMarket capitalization,the total value of publicly traded biotech companies at market prices,was$360 billion as of early April 2008.U.S.Biotechnology IndustryRevenuesnThe biotechnology industry has more than seven times in size since 1992,with revenues increasing from$8 billion in 1992 t

    19、o$58.8 billion in 2006.U.S.Biotechnology IndustryEmployees(2006)nThe U.S.biotechnology industry currently employs 1.3 million people;thats more than all the people employed by the toy and sporting goods industries.U.S.Biotechnology IndustryResearch and Development(R&D)n Biotechnology is one of the m

    20、ost research intensive industries in the world.The U.S.biotech industry spent$27.1 billion on research and development in 2006.n The top five biotech companies spent an average of$170,000 per employee on R&D in 2007.2007a banner year for biotech nFor the second year in a row,biotech financing reache

    21、d new heights.At$53 billion,fundraising grew by 13%,mostly as a result of partnership deals,which expanded by almost one-third to$22 billion.Venture capital also jumped to$7 billion,with more firms receiving funding.Initial public offering funds also rose 50%to$3 billion,mostly during the first half

    22、 of 2007.In contrast,follow-ons declined substantially by 22%,and were particularly hard hit after June.Global biotech initial public offerings Global biotech industry financing Global biotech venture capital investment 中国国家食品药品监督管理局(the State Food and Drug Administration,SFDA)nhttp:/ 新药审批办法U.S.Biot

    23、echnology IndustryRegulatory AgenciesnThe biotech industry is regulated by the Food and Drug Administration(FDA)the Environmental Protection Agency(EPA)the Department of Agriculture(USDA).Preclinical TestingnA pharmaceutical company conducts laboratory and animal studies to show biological activity

    24、of the compound against the targeted disease,and the compound is evaluated for safety.Investigational New DrugApplication(IND)n After completing preclinical testing,a company files an IND with the U.S.Food and Drug Administration(FDA)to begin to test the drug in people.n The IND becomes effective if

    25、 FDA does not disapprove it within 30 days.Investigational New DrugApplication(IND)nThe IND shows results of previous experiments:n how,where and by whom the new studies will be conducted;n the chemical structure of the compound;n how it is thought to work in the body;n any toxic effects found in th

    26、e animal studies;andn how the compound is manufactured.Investigational New DrugApplication(IND)n All clinical trials must be reviewed and approved by the Institutional Review Board(IRB,机构审查委员会)where the trials will be conducted.n Progress reports on clinical trials must be submitted at least annuall

    27、y to FDA and the IRB.Clinical Trials,Phase In These tests involve about 20 to 100 normal,healthy volunteers.n The tests study a drugs safety profile,including the safe dosage range.n The studies also determine how a drug is absorbed,distributed,metabolized,and excreted as well as the duration of its

    28、 action.Clinical Trials,Phase IInIn this phase,controlled trials of approximately 100 to 500 volunteer patients(people with the disease)assess a drugs effectiveness.Clinical Trials,Phase IIIn This phase usually involves 1,000 to 5,000 patients in clinics and hospitals.n Physicians monitor patients c

    29、losely to confirm efficacy and identify adverse events.New Drug Application(NDA)nFollowing the completion of all three phases of clinical trials,a company analyzes all of the data and files an NDA with FDA if the data successfully demonstrate both safety and effectiveness.New Drug Application(NDA)n

    30、The NDA contains all of the scientific information that the company has gathered.NDAs typically run 100,000 pages or more.n The average NDA review time for 21 new molecular entities(NMEs)approved by the FDA in 2003 was 16.9 months.Approvaln Once FDA approves an NDA,the new medicine becomes available

    31、 for physicians to prescribe.n A company must continue to submit periodic reports to FDA,including any cases of adverse reactions and appropriate quality-control records.n For some medicines,FDA requires additional trials(Phase IV)to evaluate long-term effects.Drug Discovery,Development andApproval

    32、Process-costnOn average,it costs a company$897 million to get one new medicine from the laboratory to U.S.patients,according to a November 2003 report by the Tufts Center for the Study of Drug Development.n$500 million January 1996n$359 million February 1993Outline Outline n1 Introduction to Pharmac

    33、eutical Biotechnology n2 drug target discovery,lead discovery and validation and screening drug target discovery 1).functional genomics 2).Proteome 3).yeast two-hybrid and three-hybrid 2 drug target discovery,lead discovery and validation and screening lead discovery and validation 4).reverse two-hy

    34、brid 5).combinatorial chemistry 6).phage display 7).yeast display 8).ribosome display 9).gene knockout and animal model 10).RNA Interference 11).Directed evolution and target mutagenesis screening 12).High throughput screeningOutlineOutlinen3 Expression Systems of Recombinant Proteinsn4 Purification

    35、 of Recombinant Proteinsn5 Recombinant Protein Pharmaceuticalsn6 Monoclonal Antibody-Based Pharmaceuticalsn7 Modern Vaccinesn8 Biophysical and Biochemical Analyses of Biopharmaceuticals and Formulation of Biopharmaceuticals OutlineOutlinen9 Gene Therapyn10 Bioreactorsn11 Cell engineering and Tissue

    36、engineeringn12 Patenting biotechnology inventions 2 drug target discovery,lead discovery and validation and screening drug target discoverydrug target discovery nfunctional genomicsnproteomenyeast two-hybrid and three-hybrid 2 drug target discovery,lead discovery and validation and screening lead di

    37、scovery and validationn1.reverse two-binatorial chemistryn3.phage displayn4.yeast displayn5.ribosome displayn6.gene knockout and animal modeln7.RNA Interferencen8.Directed evolution and target mutagenesis2 drug target discovery,lead discovery and validation and screening ScreeningnHigh throughput sc

    38、reening 3 Expression Systems of Recombinant Proteins na)E.colinb)Yeastnc)Insectnd)mammalian 4 Purification of Recombinant Proteins nAffinity ChromatographynProtein PrecipitationnIonic Exchange ChromatographynHydrophobic Interaction ChromatographynSize-Exclusion ChromatographynMembrane technologynEle

    39、ctrophoresis nHPLC5 Recombinant Protein PharmaceuticalsnProduct Company SystemnBlood coagulation factors(VII,VIII,IX)Novo-Nordisk/Bayer/Centeon BHK cellsnGenetics Baxter/Centeon/Wyeth CHO cellsnCalcitonin Unigene Escherichia coli/CHO cellsnDNase(cystic fibrosis)Roche CHO cellsnErythropoetin JanssenC

    40、ilag/Amgen/Boehringer CHO cellsnDarbepoetin Amgen CHO cellsnFollicle stimulating hormone(follitropin)Serono/Organon CHO cellsnLuteinization hormone Serono CHO cellsnGonadotropin Serono CHO cellsnGlucagon Novo-Nordisk Saccharomyces cerevisiaenGlucocerebrosidase(Gaucher disease)Genzyme CHO cellsnGrowt

    41、h hormones(somatotropines)Pharmacia&Upjohn/Lilly/nNovo-Nordisk/Ferring/GenentechnE.colinSerono Mouse cell linenSerono/Bio-Technology General Corp CHO cells 6 Monoclonal Antibody-Based Pharmaceuticals nKhler and Milstein found a way to combine the unlimited growth potential of myeloma cells with the

    42、predetermined antibody specificity of normal immune spleen cells.nThey did this by literally fusing myeloma cells with antibody-secreting cells from an immunized mouse.The technique is called somatic cell hybridization.The result is a hybridoma.7 Modern Vaccines nKilled whole organismsnAttenuated or

    43、ganismsnAttenuated virusnGene engineered vaccinenPeptide vaccinenDNA Vaccines 8 Biophysical and Biochemical Analyses of Biopharmaceuticals and Formulation of Biopharmaceuticals nMolecular weight,isoelectric point,hydrophobicity,etc.nKm,Vmax,etc.nLiposomesnPEG modification9 Gene Therapy nusing retrov

    44、iral vectors nusing an adeno-associated virus(AAV)vector nusing no vector 10 Bioreactors10 Bioreactors nMammary gland-specific gene expression appears not to be mediated by a single transcription factor,but instead requires cooperative interactions among several factors.Signal transduction pathways

    45、regulated by lactogenic hormones result in transcription factor binding and interaction within these elements,chromatin-structure changes,and milk-protein gene expression.10 Bioreactors10 BioreactorsnIntragenic sequences in the 5 and 3 untranslated regions of the beta-casein and WAP mRNAs,respective

    46、ly,also appear crucial for the efficient expression of these genes.Vectors to target the expression of heterologous genes,such as insulin-like growth factor I,to the mammary gland can be designed.This technology can be used to manipulate milk composition in transgenic animals,one result being improv

    47、ed infant formulas.11 Cell engineering and 11 Cell engineering and Tissue engineering Tissue engineering nUsing Stem Cells for Human Therapy:where no autologous stems cells are available,there may be a solution using somatic-cell nuclear transfer Stem cellsStem cellsSomatic cloningSomatic cloningque

    48、stionsnHow to reduce ionic strength with a simple approach?nWhat is the basis for yeast two-hybrid system?How would Reverse two-hybrid system work?nWhy cant Size-Exclusion Chromatography be used in the initial stages of protein purification?nHow to select a protein expression host?nWhy would some people be allergic to monoclonal antibodies?nWhy wouldnt a pregnant woman reject her baby?nWhy wouldnt children reject ascarid in their bodies?

    展开阅读全文
    提示  163文库所有资源均是用户自行上传分享,仅供网友学习交流,未经上传用户书面授权,请勿作他用。
    关于本文
    本文标题:大学精品课件:生物工程制药课件:lec 1 2013 old.ppt
    链接地址:https://www.163wenku.com/p-5259813.html

    Copyright@ 2017-2037 Www.163WenKu.Com  网站版权所有  |  资源地图   
    IPC备案号:蜀ICP备2021032737号  | 川公网安备 51099002000191号


    侵权投诉QQ:3464097650  资料上传QQ:3464097650
       


    【声明】本站为“文档C2C交易模式”,即用户上传的文档直接卖给(下载)用户,本站只是网络空间服务平台,本站所有原创文档下载所得归上传人所有,如您发现上传作品侵犯了您的版权,请立刻联系我们并提供证据,我们将在3个工作日内予以改正。

    163文库